A&M Perspectives: How asset light pharmaceutical companies can augment value creation in a disrupted market environment
Over the past two decades, originator pharmaceutical businesses have increasingly disposed of late-stage drug portfolios to third parties. This has spurred the growth of asset-light pharmaceutical companies with radically different operating models. Operating through networks of Contract Development and Manufacturing Organisations (CDMOs), these businesses avoid major capital expenditure, have greater flexibility, and can therefore focus on critical capabilities such as supply chain excellence, market authorisation and technical transfers.
While there are advantages, asset-light models are complex. Many different partners are involved, comprising of specialised CDMOs, distribution partners and a mix of in-house sales and country distributors. This leads to challenges related to demand planning, inventory control and cost control.
At the same time, asset-light pharma businesses are having to respond to global challenges including rising inflation, supply chain disruptions, Covid-19 outbreaks and growing geopolitical tensions.
Based on our experiences of delivering change for a range of asset-light pharmaceutical companies across Europe, we recommend five levers of value creation.
Five value levers for asset-light pharmaceutical businesses
- CDMO rationalisation and technical transfer excellence
- S&OP/ IBP upgrades
- Inventory and working capital optimisation
- Logistics simplification
- Digital tools deployment (commercial focus)
Download
Related Insights
Shocks to global supply chains are increasing in frequency and severity. Russia’s invasion of Ukraine, new Covid outbreaks in China and rising interest rates in the US are occurring at once with ramifications for global trade. What steps can companies take to improve supply chain resilience.
The Affordability Agenda: Inside Healthcare's Cost Crisis
July 14, 2026
What will it take to bend the healthcare cost curve? Jay Khosla, Chief Government Affairs Officer at Humana, joins A&M's Craig Savage and David Shulkin, M.D. to examine the financial realities shaping healthcare's future and discuss how transparency, value-based care and responsible AI adoption can help drive better outcomes.
Bridging Care and Strategy: Luis Garcia's Journey to Leader of RUSH Medical Group
July 7, 2026
Healthcare's biggest challenges won't be solved by clinicians or administrators alone. Luis Garcia, M.D, FACS, FACHE, President of RUSH Medical Group joins A&M Healthcare Industry Group's Chris Smedley and David Shulkin, M.D. to discuss why collaboration across clinical and executive leadership is essential to improving care, strengthening organizations and preparing future healthcare leaders.
Value-Based Care: From Experimentation to Enterprise Discipline
June 24, 2026
As health systems approach another round of the Center for Medicare and Medicaid Innovation (CMMI) program milestones,
one reality is clear: Value-based care (VBC) has fundamentally changed. Years of margin pressure and market volatility
have driven many systems to step back from risk sharing with payers to stabilize their balance sheets.
Episode 2: Don Antonucci, President and CEO, Providence Health Plan
June 16, 2026
In this episode, Don Antonucci, President and CEO of Providence Health Plan joins A&M Healthcare Industry Group's Craig Savage and Mike Epstein to share how health plans can maintain stability while delivering value to members.
